Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Depreciation: 2016-2024

Historic Accumulated Depreciation for Altimmune (ALT) over the last 9 years, with Dec 2024 value amounting to $2.2 million.

  • Altimmune's Accumulated Depreciation rose 12.05% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 12.05%. This contributed to the annual value of $2.2 million for FY2024, which is 12.05% up from last year.
  • Latest data reveals that Altimmune reported Accumulated Depreciation of $2.2 million as of FY2024, which was up 12.05% from $2.0 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Accumulated Depreciation peaked at $2.2 million during FY2024, and registered a low of $1.5 million during FY2022.
  • Over the past 3 years, Altimmune's median Accumulated Depreciation value was $2.0 million (recorded in 2023), while the average stood at $1.9 million.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first declined by 26.82% in 2022, then skyrocketed by 31.84% in 2023.
  • Yearly analysis of 5 years shows Altimmune's Accumulated Depreciation stood at $1.6 million in 2020, then increased by 28.03% to $2.0 million in 2021, then fell by 26.82% to $1.5 million in 2022, then surged by 31.84% to $2.0 million in 2023, then grew by 12.05% to $2.2 million in 2024.